Introduction
============

With increasing incidence and mortality, lung cancer has become the leading cause of cancer-related death and a challenging clinical problem worldwide \[[@b1-crt-2016-133]\]. Non-small cell lung cancer is a major type of lung cancer accounting for 80% of lung cancer cases. Despite the development of early diagnostic modalities and tumor markers, it is often diagnosed at an advanced stage and the 5-year survival rate is less than 20% \[[@b2-crt-2016-133]\]. Despite increasing use of targeted agents including epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and anaplastic lymphoma kinase (ALK) inhibitor for treatment of lung cancer, platinum-based combination chemotherapy is still the standard first-line treatment for non-small cell lung cancer (NSCLC), particularly for tumors without *EGFR* mutation or ALK translocation \[[@b3-crt-2016-133]\].

The discovery and clinical application of biomarkers is critical not only for early detection of the disease but also for the identification of patients expected to show the best response to therapy. Despite numerous studies, there is no biomarker with clinical significance for the prediction of outcomes after platinum-based chemotherapy. The *KRAS* mutation, despite its association with poor survival of NSCLC patients in several studies \[[@b4-crt-2016-133],[@b5-crt-2016-133]\], does not appear to be predictive of chemotherapeutic efficacy \[[@b6-crt-2016-133],[@b7-crt-2016-133]\]. Excision repair cross-complementation group 1 (ERCC1) has been linked with resistance to platinum-based chemotherapy in NSCLC \[[@b8-crt-2016-133],[@b9-crt-2016-133]\]. Low ERCC1 levels are related to increased recurrence in untreated patients after lung resection and correlated with prolonged survival of NSCLC patients treated with platinum-based adjuvant and palliative chemotherapy \[[@b10-crt-2016-133]-[@b12-crt-2016-133]\]. However, ERCC1-tailored chemotherapy failed to prove its utility in a prospective randomized trial \[[@b13-crt-2016-133]\]. Thus, discovery of novel biomarkers is needed to improve therapeutic outcomes.

Reactive oxygen species modulator 1 (Romo1) is a novel protein first cloned from head and neck cancer tissue in 2006. It is located in the mitochondrial membrane and is a key modulator of intracellular reactive oxygen species \[[@b14-crt-2016-133]\]. Upregulation of Romo1 was reported in a variety of cancer cells and Romo1-induced reactive oxygen species (ROS) production is essential for the proliferation of both normal and cancer cells \[[@b15-crt-2016-133]\]. Interestingly, Romo1-derived ROS production is related to chemoresistance in lung cancer cells \[[@b16-crt-2016-133]\]. In a recent study, we demonstrated that Romo1 expression is increased in lung tumor tissue compared to normal surrounding tissue \[[@b17-crt-2016-133]\]. In addition, we found that serum Romo1 levels are significantly increased in lung cancer patients as compared to a cancer-free population \[[@b17-crt-2016-133]\], and that Romo1 overexpression was associated with poor clinical outcome in NSCLC patients who underwent surgical resection \[[@b18-crt-2016-133]\]. However, few studies regarding the clinical implications of Romo1 in advanced NSCLC have been reported.

The aim of this study is to examine the question of whether Romo1 protein expression is associated with responses to treatment and survival rates in NSCLC patients who received platinum-based chemotherapy.

Materials and Methods
=====================

1. Patients and data collection
-------------------------------

Patients with advanced NSCLC who received platinum-based doublet as first-line chemotherapy at Korea University Anam Hospital from May 2008 to March 2010 were recruited retrospectively. Formalin-fixed paraffin-embedded tumor specimens acquired by percutaneous needle biopsy or endoscopic bronchial biopsy were used for evaluation of Romo1 expression. Patients who died within 1 month after diagnosis, those with a history of other cancers, and those who had received chemotherapy or radiation therapy were excluded. During the study period, of 123 patients who underwent first-line chemotherapy with platinum-based doublet for NSCLC, tissue specimens were available from 102 patients. Six cases were excluded because the samples were unsuitable for immunohistochemical staining, five cases were excluded due to unavailable survival data, and three cases were excluded according to the exclusion criteria. Thus, a total of 88 patients were enrolled.

All patients underwent chest computed tomography, brain magnetic resonance imaging, and ^18^F-fluorodeoxyglucose positron emission tomography for clinical staging determined according to the International Association for the Study of Lung Cancer TNM staging classification of NSCLC \[[@b13-crt-2016-133]\]. Clinical data were reviewed retrospectively from the medical records. Tumor response was examined by computed tomography every two cycles and evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) \[[@b19-crt-2016-133]\]. The study protocol was approved by the clinical research ethics committee of Korea University Anam Hospital.

2. Quantification of Romo1 protein expression
---------------------------------------------

Romo1 protein expression was measured by immunohistochemical staining. Four-micron-thick sections were prepared for each specimen and the staining was performed using a BOND-MAX Immunoautostainer (Leica Biosystems, Newcastle Upon Tyne, UK). Slides were heated at 98°C for 20 minutes and cooled for 10 minutes in Epitope Retrieval Solution 1 and 0.01 M citrate buffer (pH 6.0), respectively. Slides were then washed in distilled water, followed by blocking of endogenous peroxidase activity using a Bond Polymer Refine Detection Kit (Leica Biosystems) for 5 minutes. Slides were washed and placed in Tris-buffered saline, followed by incubation for 30 minutes with a Romo1 monoclonal antibody (OriGene Technologies, Rockville, MD) at a 1:200 dilution. Sections were developed with 3,3′-diaminobenzidine chromogen solution for 7 minutes, counterstained with hematoxylin, and dehydrated. Human colon adenocarcinoma tissue was used as a positive control, and slides stained without the primary antibody were used as a negative control.

Histopathological assessment was performed separately by two investigators (S.H.L. and S.I.C.) and then a consensus was made on discordant assessment. Stained cells were interpreted as positive when cytoplasmic staining was identified. Staining intensities of individual cells were graded as 0 (no staining), 1 (weak), 2 (distinct), or 3 (strong), and the percentages of cells with these staining intensities were calculated. Finally, histological scores (H scores) were calculated by multiplying staining intensities by the percentages of cells with each staining intensity (possible range, 0 to 300).

3. Statistical analyses
-----------------------

The cutoff H score for discriminating between low and high Romo1 expression was defined as the point with the lowest p-value on the log-rank test for all possible H scores. Clinical outcomes were assessed using response rate (RR), progression-free survival (PFS), and overall survival (OS). RR was defined as the percentage of patients with CR and PR among the population. PFS was defined as the time from the first day of chemotherapy to disease progression or death from any cause. OS was defined as the time from the first day of chemotherapy to death from any cause. Chi-square test or Fisher exact test was used as appropriate for analysis of the proportions of low and high H scores in the different patient groups. Associations between clinical parameters and survival were first evaluated by univariate analysis using the log-rank test, and multivariate Cox's proportional hazard regression was performed with adjustment for parameters with p-values of less than 0.3 in the univariate analysis. Survival curves were generated using the Kaplan-Meier method. p-values of less than 0.05 were considered significant. Statistical analyses were performed using SPSS ver. 19.0 for Windows (SPSS Inc., Chicago, IL).

Results
=======

1. Patients' characteristics
----------------------------

The clinical characteristics of the study population are summarized in [Table 1](#t1-crt-2016-133){ref-type="table"}. All subjects were Korean and the median age was 69 years (range, 39 to 81 years). Sixty-five patients (74%) were male, and 57 patients (65%) were over 65 years of age. Sixty-three patients (72%) were current or former smokers. Fifty-nine patients (67%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and 25 patients (28%) were stage IIIB and 63 patients (72%) were stage IV. Twenty-five patients (28%) had well-differentiated cancer and 63 patients (72%) had moderately-to poorly-differentiated cancer. Fifty patients (57%) had adenocarcinoma and 38 patients (43%) had squamous cell carcinoma. *EGFR* mutation analysis was performed in only 16 adenocarcinoma patients; six patients (37%) were positive for the activating mutation while 10 patients (63%) were negative.

The chemotherapy regimens used for first-line treatment were pemetrexed/platinum (n=30, 34%), gemcitabine/platinum (n=36, 40%), paclitaxel/platinum (n=14, 16%), and docetaxel/platinum (n=8, 9%). The median number of cycles of first-line chemotherapy was 4 (range, 1 to 9). Of the 88 patients, 48 patients (54.0%) underwent second-line or later treatment during the follow-up period. Second-line treatment regimens were gemcitabine/vinorelbine (n=11, 23%), pemetrexed (n=14, 29%), docetaxel (n=4, 8%), erlotinib (n=10, 21%), and gefitinib (n=9, 20%). Twenty-one patients underwent third-line treatment with gemcitabine/vinorelbine (n=8, 38%), pemetrexed (n=3, 14%), docetaxel (n=2, 9%), or gefitinib (n=8, 38%).

2. Romo1 protein expression
---------------------------

Representative slides with different H scores are shown in [Fig. 1](#f1-crt-2016-133){ref-type="fig"}. Romo1 protein was primarily localized to the cytoplasm of cancer cells. The Romo1 H scores were normally distributed with a median of 180.7 (range, 17 to 295).

3. Relationship between Romo1 expression and clinical parameters
----------------------------------------------------------------

The optimal cutoff H score determined for discriminating between low and high Romo1 expression was 200. Using this cutoff, 53 patients (60%) were allocated to the low Romo1 group and 35 patients (40%) to the high Romo1 group.

To determine which clinical parameters are associated with the level of Romo1 expression, we compared the proportion of low and high Romo1 expression in the different patient groups. There was no difference in the proportion of patients with low and high Romo1 expression in all patients groups ([Table 1](#t1-crt-2016-133){ref-type="table"}). This result indicates that none of the clinical parameters including age, sex, smoking status, performance status, stage, tumor differentiation, or histological type were associated with Romo1 expression.

4. Relationship between Romo1 protein expression and RR
-------------------------------------------------------

Forty-one patients (46%) showed PR, 11 patients (12%) showed SD, and 36 patients (42%) showed PD. Thus, the overall RR was 46%. In patients with low Romo1 expression, 29 patients (55%) showed PR while 12 patients (36%) in the high Romo1 group had PR. Significantly higher RR was observed in the low Romo1 group compared with that in the high Romo1 group (p=0.017). Clinical parameters including female sex, young age, never smoker, well-differentiated cancer, and better performance status showed a trend toward a good response to treatment but were not statistically significant.

5. Relationship between Romo1 expression and PFS
------------------------------------------------

Results of survival analyses according to the clinical parameters are summarized in [Table 2](#t2-crt-2016-133){ref-type="table"}. The median PFS for the whole population was 6.7 months (95% confidence interval \[CI\], 2.2 to 10.8). In the univariate analysis, poor performance, advanced T stage, advanced stage, and squamous histology showed association with poor PFS, and high Romo1 expression showed association with poor PFS (4.5 months vs. 9.8 months, p \< 0.001). In the multivariate analysis, advanced stage (hazard ratio \[HR\], 1.78; 95% CI, 1.07 to 2.96) and high Romo1 expression (HR, 2.75; 95% CI, 1.71 to 4.44) showed significant association with poor PFS. Kaplan-Meier survival curves showed that poor survival was likely in terms of PFS for patients with high Romo1 expression ([Fig. 2A](#f2-crt-2016-133){ref-type="fig"}).

6. Relationship between Romo1 expression and OS
-----------------------------------------------

The median OS for all study subjects was 12.5 months (95% CI, 9.8 to 15.5). In univariate analysis, poor performance status and advanced stage showed significant association with poor OS, and high Romo1 expression also showed significant association with poor OS (15.5 months vs. 8.4 months, p \< 0.001). In multivariate analysis, male gender (HR, 2.58; 95% CI, 1.49 to 4.46), poor performance status (HR, 2.42; 95% CI, 1.47 to 3.99), advanced stage (HR, 1.84; 95% CI, 1.09 to 3.10), and high Romo1 expression (HR, 3.99; 95% CI, 2.36 to 6.74) showed significant association with poor OS. Kaplan-Meier survival curves showed that poor survival in terms of OS was likely in patients with high Romo1 expression ([Fig. 2B](#f2-crt-2016-133){ref-type="fig"}).

7. Subgroup analyses according to tumor histology
-------------------------------------------------

Further survival analyses were performed according to tumor histology. The median PFS of patients with adenocarcinoma was 8.8 months (95% CI, 4.6 to 12.5). In univariate analysis patients with adenocarcinoma, male gender, smoking history, advanced stage, and high Romo1 expression showed significant association with poor PFS and in multivariate analysis, high Romo1 expression showed association with poor PFS (HR, 2.43; 95% CI, 1.42 to 3.67). In terms of OS, the median survival was 14.6 months (95% CI, 11.7 to 17.4). In univariate analysis, old age, smoking history, poor performance, advanced stage, and high Romo1 expression showed significant association with poor OS. In multivariate analysis, poor performance (HR, 2.91; 95% CI, 1.46 to 5.79), advanced stage (HR, 1.87; 95% CI, 1.16 to 3.81), and high Romo1 expression (HR, 2.08; 95% CI, 1.03 to 4.21) showed significant association with shorter OS.

In patients with squamous cell carcinoma, the median PFS was 4.5 months (95% CI, 2.7 to 7.1). In univariate analysis high Romo1 expression showed association with poor PFS, and in the multivariate analysis, high Romo1 expression showed significant association with poor PFS (HR, 4.41; 95% CI, 2.94 to 8.69). In terms of OS, the median survival was 9.8 months (95% CI, 6.8 to 12.4). In univariate analysis advanced stage and high Romo1 expression showed association with poor OS, and in the multivariate analysis, advanced stage (HR, 1.15; 95% CI, 1.07 to 2.38) and high Romo1 expression (HR, 3.30; 95% CI, 2.65 to 9.10) showed significant association with poor OS. The Kaplan-Meier survival curves showed that poor survival in terms of PFS and OS in both cell types was likely for patients with high Romo1 expression.

Discussion
==========

In the current study, Romo1 overexpression was significantly associated with poor PFS and OS in advanced NSCLC patients who received platinum-based chemotherapy as first line treatment. These findings were consistent regardless of tumor histology. To the best of our knowledge, this is the first study demonstrating the relation of Romo1 expression to clinical outcome as well as its potential as a predictive marker in advanced NSCLC.

Although Romo1 was discovered a decade ago, the clinical significance of this protein is not well known. Several *in vitro* studies have suggested possible involvement of Romo1 in many steps in carcinogenesis, including tumor progression and invasion \[[@b14-crt-2016-133],[@b16-crt-2016-133],[@b20-crt-2016-133],[@b21-crt-2016-133]\]. Based on our previous findings \[[@b17-crt-2016-133],[@b18-crt-2016-133]\], we hypothesized that Romo1 might have clinical implications in advanced lung cancer. The current study demonstrates the potential of Romo1 in prediction of clinical outcomes not only in early stage lung cancer but also in advanced disease. In addition, the consistently positive findings of Romo1 in lung cancers may provide a foundation for future studies examining the clinical usefulness of this protein in other malignancies.

Although the exact mechanism by which Romo1 overexpression is related to poor response and shorter survival of patients who received platinum-based treatment is unclear, adaptation to oxidative stress could be a possible explanation. Adaption involves regulation of the redox buffering system and upregulation of antioxidant enzymes required for survival of cancer cells from external stimulation or therapeutic drugs \[[@b22-crt-2016-133]\]. The anticancer activity of platinum is mainly the result of crosslinking with DNA and inhibition of DNA synthesis; however, induction and accumulation of ROS is another important mechanism involved in its activity \[[@b23-crt-2016-133]\]. Romo1 is a key mediator that maintains intracellular ROS production and is essential for survival in both normal and cancer cells \[[@b15-crt-2016-133],[@b24-crt-2016-133]\]. Thus, we can hypothesize that Romo1-induced ROS production enhances expression of various antioxidants, resulting in chemoresistance to platinumrelated oxidative stress. Although further *in vitro* studies are required to confirm our hypothesis, it is supported by a previous finding that Romo1 is responsible for upregulation of antioxidant enzymes and the adaptive response to 5-fluorouracil treatment in lung cancer cells \[[@b16-crt-2016-133]\].

In the current study, we found no difference in expression levels of Romo1between adenocarcinoma and squamous cell carcinoma, and the association between Romo1 expression and clinical outcome was similar regardless of tumor histology. This result is consistent with those of previous studies reporting Romo1 overexpression in NSCLC patients with both cell types \[[@b17-crt-2016-133],[@b18-crt-2016-133]\]. Based on these findings, Romo1 overexpression can be considered as a common phenomenon and Romo1 has potential as a novel biomarker applicable to both cell types. However, considering the relatively closer relationship with cigarette smoking and the less frequent association of driving mutations in squamous cell carcinoma than in adenocarcinoma, further experiments are required to elucidate possible differences in the clinical implications of Romo1 between different cell types.

There are several limitations in this study. First, this study was conducted retrospectively at a single institution and included a relatively small sample size. Second, immunohistochemical staining was performed for the quantification of Romo1 protein expression, which may be less sensitive than other methods. However, a standard quantification method for Romo1 expression has not been established and immunohistochemistry is a widely used method for measurement of protein expression. Third, *EGFR* mutation data were available in only a small proportion of the subjects; therefore, analysis of the relationship between EGFR status and Romo1 expression was not possible. Most of our study subjects were enrolled before the IPASS trial \[[@b25-crt-2016-133]\]; since that trial *EGFR* mutation analysis has become an essential test for newly-diagnosed NSCLC patients.

Conclusion
==========

In summary, Romo1 showed potential as an adverse predictive marker in NSCLC patients treated with platinum-based chemotherapy. Further large-scale investigations are required to determine the clinical implications of Romo1 in different clinical settings involving patients treated with targeted agents and using different quantification methods.

Conflict of interest relevant to this article was not reported.

![Representative samples of immunochemical staining for Romo1 with different H scores (×200). Romo1 was primarily detected in the cytoplasm of adenocarcinoma and squamous cell carcinoma cells. (A) H score of 50. (B) H score of 150. (C) H score of 250. Romo1, reactive oxygen species modulator 1; H scores, histological scores; ADC, adenocarcinoma; SQCC, squamous cell carcinoma.](crt-2016-133f1){#f1-crt-2016-133}

![Kaplan-Meier survival curves for progression-free survival (PFS) (A) and overall survival (OS) (B) in the overall population. p-values were determined using the log-rank test. Romo1, reactive oxygen species modulator 1.](crt-2016-133f2){#f2-crt-2016-133}

###### 

Clinical characteristics of patients according to low and high Romo1 expression

  Variable                                                             No. of patients (%)   Romo1 expression   p-value   
  -------------------------------------------------------------------- --------------------- ------------------ --------- ---------
  **Total**                                                            88 (100)              53 (60)            35 (40)   
  **Sex**                                                                                                                 
   Female                                                              23 (26)               13 (25)            10 (29)   0.672
   Male                                                                65 (74)               40 (75)            25 (71)   
  **Age (yr)**                                                                                                            
   \< 65                                                               31 (35)               22 (42)            9 (26)    0.129
   ≥ 65                                                                57 (65)               31 (58)            26 (74)   
  **Smoking**                                                                                                             
   Never                                                               25 (28)               15 (28)            10 (29)   0.978
   Ever                                                                63 (72)               38 (72)            25 (71)   
  **ECOG PS**                                                                                                             
   0, 1                                                                59 (67)               35 (66)            24 (69)   0.804
   ≥ 2                                                                 29 (33)               18 (34)            11 (31)   
  **T stage**                                                                                                             
   T1                                                                  7 (8)                 3 (6)              1 (3)     0.645
   ≥ T2                                                                81 (92)               49 (94)            34 (97)   
  **N stage**                                                                                                             
   N0                                                                  9 (10)                5 (10)             3 (9)     \> 0.99
   ≥ N1                                                                79 (90)               47 (90)            32 (91)   
  **Stage**                                                                                                               
   IIIB                                                                25 (28)               16 (30)            9 (26)    0.648
   IV                                                                  63 (72)               37 (70)            26 (74)   
  ***EGFR* mutation^[a)](#tfn1-crt-2016-133){ref-type="table-fn"}^**                                                      
   Positive                                                            6 (37)                3 (33)             3 (43)    0.781
   Negative                                                            10 (63)               6 (67)             4 (57)    
  **Differentiation**                                                                                                     
   Well                                                                61 (69)               39 (74)            22 (63)   0.285
   Mod-poor                                                            27 (31)               14 (26)            13 (37)   
  **Tumor histology**                                                                                                     
   ADC                                                                 50 (57)               32 (60)            18 (51)   0.171
   SQCC                                                                38 (43)               23 (40)            15 (49)   
  **First-line treatment**                                                                                                
   Pemetrexed/Platinum                                                 30 (34)               16 (53)            14 (47)   0.948
   Gemcitabine/Platinum                                                36 (40)               20 (56)            16 (44)   
   Paclitaxel/Platinum                                                 14 (16)               8 (57)             6 (43)    
   Docetaxel/Platinum                                                  8 (9)                 4 (50)             4 (50)    

Romo1, reactive oxygen species modulator 1; ECOG PS, Eastern Cooperative Oncology Group performance status; T, tumor; N, lymph node; EGFR, epidermal growth factor receptor; ADC, adenocarcinoma; SQCC, squamous cell carcinoma.

*EGFR* mutation data were available in 16 adenocarcinoma patients.

###### 

Results of survival analyses according to clinicopathological parameters in all study subjects

  Variable               No. of patients (%)   PFS    OS                                              
  ---------------------- --------------------- ------ ---------- ------------------ ------ ---------- ------------------
  **All**                88 (100)              6.7                                  12.5              
  **Sex**                                                                                             
   Female                23 (26)               7.1    0.154      NA                 15.8   0.077      Reference
   Male                  65 (74)               5.9                                  12.2              2.58 (1.49-4.46)
  **Age (yr)**                                                                                        
   \< 65                 31 (35)               8.3    0.606      NA                 14.6   0.099      Reference
   ≥ 65                  57 (65)               5.5                                  11.3              1.18 (0.73-1.93)
  **Smoking**                                                                                         
   Never                 25 (28)               5.8    0.311      NA                 15.5   0.105      NA
   Ever                  63 (72)               7.3                                  12.3              
  **ECOG PS**                                                                                         
   0, 1                  59 (67)               7.8    0.048      Reference          14.4   0.003      Reference
   ≥ 2                   29 (33)               5.0               1.28 (0.79-2.06)   9.2               2.42 (1.47-3.99)
  **T stage**                                                                                         
   T1                    7 (8)                 11.2   0.036      Reference          11.8   0.912      NA
   ≥ T2                  81 (92)               6.4               2.73 (0.82-9.03)   12.4              
  **N stage**                                                                                         
   N0                    9 (10)                8.5    0.392      NA                 12.5   0.699      NA
   ≥ N1                  79 (90)               6.1                                  12.0              
  **Stage**                                                                                           
   IIIB                  25 (28)               8.5    0.019      Reference          15.6   0.017      Reference
   IV                    63 (72)               5.3               1.78 (1.07-2.96)   12.1              1.84 (1.09-3.10)
  **Differentiation**                                                                                 
   Well                  25 (28)               6.8    0.318      NA                 13.1   0.821      NA
   Mod-poor              63 (72)               8.2                                  9.8               
  **Tumor histology**                                                                                 
   ADC                   61 (69)               8.6    0.019      Reference          14.5   0.306      NA
   SQCC                  27 (31)               4.2               1.70 (1.07-2.68)   9.6               
  **Romo1 expression**                                                                                
   Low                   50 (57)               9.8    \< 0.001   Reference          15.5   \< 0.001   Reference
   High                  38 (43)               4.5               2.75 (1.71-4.44)   8.4               3.99 (2.36-6.74)

PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; T, tumor; N, lymph node; ADC, adenocarcinoma; SQCC, squamous cell carcinoma; Romo1, reactive oxygen species modulator 1.
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